Samplimy wins Money Talks Pitch Competition: aiming to transform the future of sampling

With a technology that enables painless and more accessible sampling, Samplimy took home first prize in the Money Talks Pitch Competition at the second Life Science Fair Flemingsberg of the year.

The medtech company develops solutions for microsampling, where biomarkers* are collected through painless methods directly from the skin. The technology is based on more than five years of research at KTH Royal Institute of Technology, and makes it possible for patients to collect samples of both blood and interstitial fluid (ISF)* themselves – without the use of traditional needles or the need to visit a clinic.

Samplimy is about unlocking access to biodata at frequency and scale by providing patient-centric sampling of blood and interstitial fluid. Today, clinical trials are expensive due to complex logistics and patients struggling with painful blood collection and repeated clinic visits. Our technology enables self-sampling that you barely notice, allowing for more time points and richer real-world data needed for the revolution we see in omics and AI models to deliver entirely new insights. In addition, microsampling can open the door to diagnostics for large parts of the global population currently lacking basic access, with the goal of facilitating healthcare’s shift toward more preventive and predictive care, says CEO Patrik Nilsson.

Their first product, which focuses on ISF and is aimed at researchers and life science companies within dermatology and skincare, is already being used in research studies and pilot projects. The latter for example together with Procter & Gamble in the US. At the same time, the company is also developing a blood-based product, with the aim of enabling more patient-friendly and decentralized clinical studies and screening programs.

Looking ahead, Samplimy’s focus is on scaling up the organization and product development, expanding ongoing collaborations and pilot studies, and initiating new studies. The win in the Money Talks Pitch Competition they view as a positive step in going forward.

The win means a lot, both as a stamp of quality and as confirmation that colleagues, investors, and the market see the same needs that we do – and that the hard work we put in is truly relevant”, says Patrik.

 

Interstitial fluid is the fluid found between cells in the body’s tissues and serves as a local source of information about what is happening in the body, where it happens.

Biomarkers are measurable indicators in the body that can provide information about health or disease.

Limitless Potential: Winner of the Flemingsberg Science Award 2025

Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.

50 years of life-changing therapies

On November 12 1975, the first allogeneic bone marrrow transplantation in Sweden was performed at Huddinge Hospital, here in Flemingsberg. On November 12 1975, the first allogeneic stem cell transplantation in Sweden was performed at Huddinge Hospital, here in Flemingsberg. From nuclear catastrophe the foundations of bone marrow transplantation had emerged, and with it, the birth of modern stem cell therapy — the same principles that today underpin cell and gene therapies and CAR-T treatments.

Go to Top